Last updated 2026-07-20
- Raised $2M Seed round led by Rimonci Capital, Dec 2018
Total raised
$2.0M
Last: Undisclosed Round 2019-01
Stage
Seed
Founded
2018
Headcount
5
HQ
Kensington, United States
Sector
Health Tech & Life Sciences
About
Galimedix Therapeutics is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Their groundbreaking small molecules aim to change the course of diseases where amyloid beta (Aβ) plays a role, such as dry age-related macular degeneration (AMD), glaucoma, and Alzheimer's disease. The company's approach blocks a key step in the neurodegenerative process with a highly specific, well-tolerated small molecule without impacting normal neuronal function. This involves preventing the formation of toxic oligomers and protofibrils of Aβ, which have emerged as a central cause of neurodegeneration.
Funding history · 1 round · $2.0M total
2018-12
Seed
$2.0M
★ Rimonci Capital★ InFocus Capital Partners
Headcount over time
From 3 (2020-04) to 11 (2026-03) · +8 (+267%) · 16 points · source: Finder history + radar grounding
Q&A
- What is Galimedix Therapeutics' primary focus?
- Galimedix Therapeutics is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies for serious eye and brain diseases, specifically targeting conditions where amyloid beta plays a role, such as dry AMD, glaucoma, and Alzheimer’s disease.
- When was Galimedix Therapeutics founded?
- Galimedix Therapeutics was founded in June 2017.
- How much funding has Galimedix Therapeutics raised to date?
- Galimedix Therapeutics has raised a total of $2,000,000.
- Which investors participated in Galimedix Therapeutics' funding round in January 2019?
- In January 2019, Galimedix Therapeutics received funding from InFocus Capital Partners and Rimonci Capital.
- What is the current employee count for Galimedix Therapeutics?
- Galimedix Therapeutics has 1-10 employees.
- Where is Galimedix Therapeutics headquartered?
- Galimedix Therapeutics is headquartered in Shorashim, Israel.
- Does Galimedix Therapeutics hold any patents?
- Yes, Galimedix Therapeutics holds 1 patent.
- Who are the co-founders of Galimedix Therapeutics?
- The co-founders of Galimedix Therapeutics are Christopher Parsons, Herman Russ, and Andrew Pearlman.
Team · 5
Andrew Pearlman
Founder · Founder, President, Board Member
Hermann Russ
Founder · Co-founder, Chief Scientific Officer, Board Member
Alexander Gebauer
Founder · Co-founder, Executive Chairman
Phyllis K. Bellin
Founder · Co-founder, Chief Financial Officer, Board Member
Christopher Parsons
Founder · Co-Founder, Chief Pharmacologist & VP of Non-Clinical Development
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
brain-disorderdrug-deliveryophthalmologyvisually-impairedeye-diseasesglaucomadrug-discoveryalzheimers-diseasedegenerative-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | galimedix.com |
|---|---|
| linkedin.com/company/42904523 |
Identifiers & details
| Legal name | Galimedix Therapeutics, Inc. |
|---|---|
| Founded | 2018 |
| Employees (exact) | 5 |
| Offices | Kensington |
Radar intelligence
Patents
| EPO | 7 |
|---|
Web history (Wayback)
| Domain | galimedix.com |
|---|
Certificate / subdomain footprint
| Subdomains | 9 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515669174 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2017-06-11 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | 4 שורשים |